This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Medtronic ICMs Detect High Rate of AF in Undiagnosed Patients
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently unveiled results from a new clinical study evaluating Insertable Cardiac Monitors (ICMs).
CR Bard (BCR) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of CR Bard (BCR), also known as Bard, rallied to a new 52-week high of $309.16 on May 12. Let us take a look at the key catalysts driving the stock's performance.
Varian ProBeam Proton System Gets Okayed by Shonin in Japan
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) recently announced that its flagship ProBeam system for proton therapy has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW)
Luminex (LMNX) Tops Q1 Earnings, Revenue Guidance Raised
by Zacks Equity Research
Luminex Corporation (LMNX) reported earnings of 27 cents per share in the first quarter of 2017, surpassing the Zacks Consensus Estimate of adjusted earnings of 8 cents per share by a massive 237.5%.
Luminex (LMNX) Down 4.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.
Should You Sell Luminex (LMNX) Before Earnings?
by Zacks Equity Research
Luminex (LMNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Product Stocks' Earnings on Feb 6: HAE, PAHC & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their quarterly reports on Feb 6.
Luminex Awarded R&D 100 for ARIES Systems in November
by Zacks Equity Research
Luminex Corporation (LMNX) announced that its ARIES Systems was awarded the R&D 100 Award at the 54th Annual R&D 100 Awards ceremony in November.
Luminex Projects Strong Q4 Revenues, Issues 2017 Guidance
by Zacks Equity Research
Luminex Corporation (LMNX) announced that it expects revenues in the fourth quarter of 2016 to be approximately $72 million and approximately $271 million for full-year 2016.